Brightsurf Science News & Current Events

August 30, 2014
Medication shows mixed results in reducing complications from cardiac surgery
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.

First recommendations on all new oral anticoagulants in pulmonary embolism published
The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines.

PARADIGM HF -- investigational LCZ696: A new horizon in heart failure
An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.

COPPS 2 -- Gout med cuts complications after cardiac surgery, but side-FX are high
Patients who took the anti-inflammatory drug colchicine just before cardiac surgery had a significantly lower risk of developing a common complication called post-pericardiotomy syndrome, according to a new study presented at the ESC 2014 Congress today.

ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD
The therapeutic benefit of revascularization in coronary artery disease (CAD) is emphasised in the 2014 ESC/EACTS revascularization guidelines presented at ESC Congress by joint Task Force Chairs professor Stephan Windecker of the European Society of Cardiology and professor Philippe Kolh of the European Association for Cardio-Thoracic Surgery.

First multidisciplinary recommendations on management of arrhythmias in ACS patients
The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary syndromes (ACS) are published today in EP Europace.

POPE 2 -- another anti-inflammatory fails to reduce post-surgical fluid around the heart
The anti-inflammatory drug colchicine is not an effective treatment for cardiac patients who develop a condition called post-operative pericardial effusion (POPE) -- a build-up of fluid around the heart, according to a new study.

First comprehensive ESC Guidelines on aortic diseases published
The first comprehensive ESC Guidelines on aortic diseases are published today.

CONFIRM HF-Iron deficient heart failure patients see improvement with intravenous supplementation
Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014.

Ultrasonography evaluation of peripheral nerve injuries after an earthquake
Dr. Man Lu and co-workers from Sichuan Provincial People's Hospital in China evaluated 34 patients with persistent clinical symptoms and neurologic signs of impaired nerve function.

NECTAR-HF fails to demonstrate clinical benefit of vagus nerve stimulation in Heart Failure
Stimulating the vagus nerve, which regulates the body's internal organ systems including the heart, does not improve cardiac function in heart failure patients, according to results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial.

Transvenous lead extraction clinically successful in 98 percent of cases
Transvenous lead extraction is clinically successful in more than 98 percent of cases according to data from the European Lead Extraction ConTRolled registry presented for the first time today at ESC Congress 2014 by Dr.

Sudden death predictor identifies ICD candidates in new ESC Guidelines
A new sudden death predictor for patients with hypertrophic cardiomyopathy identifies candidates for implantable cardioverter defibrillators (ICDs) in ESC Guidelines published today.

First expert consensus on ventricular arrhythmias published
The first expert consensus on ventricular arrhythmias is published today.

MORE CRT -- quadripolar lead trumps bipolar option in cardiac resynchronization
Use of a quadripolar left ventricular lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months according to preliminary Hot Line results presented today at ESC Congress 2014. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to